XL SOLACI Regional Sessions – 13° Andean region March 06th & 07th, 2020. After 3 years, SOLACI returns to Ecuador -this time to the beautiful city of Manta- to continue promoting the development of interventional cardiology in Latin America. Do not hesitate to participate in this important event that will undoubtedly be enriching for medical...
XXXIX SOLACI Regional Sessions – 14° Central América & the Caribbean Region. September 19th, 20th y 21st, 2019. After 12 years, SOLACI returns to Panamá to continue promoting the development of interventional cardiology in Latin America. Do not hesitate to participate in this important event that will undoubtedly be enriching for medical practice and, also,...
In this new era, the paradigm to treat the whole spectrum of transcatheter aortic valve replacement (TAVR) patients has started to shift beyond risk. However, broadening the spectrum raises the question of durability, which is why any long-term TAVR outcomes in any context are welcome. This specific study studied TAVR durability in the treatment of...
38th SOLACI Regional Sessions – 13° Southern Cone Region. August 23 and 24, 2019. After 2 years, SOLACI returns to Bolivia to continue promoting the development of interventional cardiology in Latin America. Do not hesitate to participate in this important event that will undoubtedly be enriching for medical practice and, also, to improve the quality of...
Long-term follow-up of patients who underwent transcatheter aortic valve replacement (TAVR) and developed left bundle branch block (LBBB) after the procedure seems reassuring. Although it is not benign, it is associated with more conduction defects, more pacemakers, and worsening ventricular function. Long-term follow-up “partially reassures” the concerns of many physicians about new LBBB after TAVR....
This angiographic substudy supports the safety of drug-coated balloons in small vessels. Despite better angiographic outcomes, there were eight cases of stent thrombosis among drug-eluting stent (DES) patients, while there was none with drug-coated balloons. In patients with small vessels, using a drug-coated balloon appears safe and comparable to DES, with favorable angiographic outcomes at...
This new analysis shows the mechanism behind the benefit of using MitraClip and the necessary degree of residual mitral regurgitation (MR) to have an impact. Regardless the intervention type, patients with cardiac failure and secondary mitral regurgitation present lower hospitalization for cardiac failure, all-cause mortality and improved quality of life the lower the MR. MitraClip...
Once more, SOLACI is proud to participate at one of the most important interventional cardiology meetings in the world: the EuroPCR 2019. Together with our European sister institution, we will conduct an important joint session on “Innovations for the treatment of complex coronary artery lesions from LATAM”, where we will touch upon topics related to...
Courtesy of Dr. Carlos Fava. Tricuspid regurgitation (TR) is more common than we thought. Around 1.6 million people in the US and over 3 million in Europe experience significant TR. It usually has a functional cause and its negative impact on patient prognosis is strong. Its surgical treatment is challenging, and it is important that its resolution...
Transcatheter mitral valve repair (TMVR) with MitraClip was shown feasible and safe, and therefore a viable option for symptomatic patients with severe mitral valve regurgitation of prohibitive risk. In this regard, the procedure alleviates symptoms, cardiac regurgitation and has a potential benefit on ventricular remodeling. However, many patients presented atrial fibrillation (AF) and mitral valve...